Timothy D Bryson1, Xiaosong Gu2, Remonda M Khalil1, Safa Khan3, Liping Zhu3, Jiang Xu3, Edward Peterson4, Xiao-Ping Yang3, Pamela Harding5. 1. Hypertension & Vascular Research Division, Dept. of Internal Medicine, USA; Dept. of Physiology, Wayne State University School of Medicine, USA. 2. Hypertension & Vascular Research Division, Dept. of Internal Medicine, USA; Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China. 3. Hypertension & Vascular Research Division, Dept. of Internal Medicine, USA. 4. Dept. of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA. 5. Hypertension & Vascular Research Division, Dept. of Internal Medicine, USA; Dept. of Physiology, Wayne State University School of Medicine, USA. Electronic address: phardin1@hfhs.org.
Abstract
BACKGROUND: Prostaglandin E2 (PGE2) signals through 4 separate G-protein coupled receptor sub-types to elicit a variety of physiologic and pathophysiological effects. We recently reported that PGE2 via its EP3 receptor could reduce cardiac contractility of isolated myocytes and the working heart preparation. We thus hypothesized that there is an imbalance in the EP3/EP4 ratio towards EP3 in the failing heart and that overexpression of EP4 in a mouse model of heart failure would improve cardiac function. METHODS AND RESULTS: Our hypothesis was tested in a mouse model of myocardial infarction (MI) with the use of AAV9-EP4 driven by the myosin heavy chain promoter to overexpress EP4 in the cardiac myocytes. Echocardiography was performed to assess cardiac function. We found that overexpression of EP4 improved shortening fraction (p = 0.0025), ejection fraction (p = 0.0003), and reduced left ventricular dimension at systole (p = 0.0013). Overexpression of EP4 also significantly reduced indices of cardiac hypertrophy and interstitial collagen fraction. Animals treated with AAV9-EP4 also had a significant decrease in TNFα mRNA expression and in the number of macrophages and T cells migrated post MI coupled with a reduction in the expression of iNOS. CONCLUSION: Overexpression of EP4 improves cardiac function post MI. This may be mediated through reductions in adverse cardiac remodeling or via inhibition of cytokine/chemokine production.
BACKGROUND:Prostaglandin E2 (PGE2) signals through 4 separate G-protein coupled receptor sub-types to elicit a variety of physiologic and pathophysiological effects. We recently reported that PGE2 via its EP3 receptor could reduce cardiac contractility of isolated myocytes and the working heart preparation. We thus hypothesized that there is an imbalance in the EP3/EP4 ratio towards EP3 in the failing heart and that overexpression of EP4 in a mouse model of heart failure would improve cardiac function. METHODS AND RESULTS: Our hypothesis was tested in a mouse model of myocardial infarction (MI) with the use of AAV9-EP4 driven by the myosin heavy chain promoter to overexpress EP4 in the cardiac myocytes. Echocardiography was performed to assess cardiac function. We found that overexpression of EP4 improved shortening fraction (p = 0.0025), ejection fraction (p = 0.0003), and reduced left ventricular dimension at systole (p = 0.0013). Overexpression of EP4 also significantly reduced indices of cardiac hypertrophy and interstitial collagen fraction. Animals treated with AAV9-EP4 also had a significant decrease in TNFα mRNA expression and in the number of macrophages and T cells migrated post MI coupled with a reduction in the expression of iNOS. CONCLUSION: Overexpression of EP4 improves cardiac function post MI. This may be mediated through reductions in adverse cardiac remodeling or via inhibition of cytokine/chemokine production.
Authors: G A Haywood; P S Tsao; H E von der Leyen; M J Mann; P J Keeling; P T Trindade; N P Lewis; C D Byrne; P R Rickenbacher; N H Bishopric; J P Cooke; W J McKenna; M B Fowler Journal: Circulation Date: 1996-03-15 Impact factor: 29.690
Authors: Mariana Morato-Marques; Marina R Campos; Steve Kane; Ana P Rangel; Casey Lewis; Megan N Ballinger; Sang-Hoon Kim; Marc Peters-Golden; Sonia Jancar; Carlos H Serezani Journal: J Biol Chem Date: 2011-06-29 Impact factor: 5.157
Authors: Racquel Domingo-Gonzalez; Samuel Katz; C Henrique Serezani; Thomas A Moore; Ann Marie Levine; Bethany B Moore Journal: J Immunol Date: 2013-04-29 Impact factor: 5.422
Authors: Junya Takagawa; Yan Zhang; Maelene L Wong; Richard E Sievers; Neel K Kapasi; Yan Wang; Yerem Yeghiazarians; Randall J Lee; William Grossman; Matthew L Springer Journal: J Appl Physiol (1985) Date: 2007-03-08
Authors: Timothy D Bryson; Jacob Ross; Edward Peterson; Pamela Harding Journal: Prostaglandins Other Lipid Mediat Date: 2019-06-20 Impact factor: 3.072
Authors: Timothy D Bryson; Teja S Pandrangi; Safa Z Khan; Jiang Xu; Tengis S Pavlov; Pablo A Ortiz; Edward Peterson; Pamela Harding Journal: Am J Physiol Heart Circ Physiol Date: 2020-03-06 Impact factor: 4.733
Authors: Matthew D Martens; Nivedita Seshadri; Lucas Nguyen; Donald Chapman; Elizabeth S Henson; Bo Xiang; Landon Falk; Arielys Mendoza; Sunil Rattan; Jared T Field; Philip Kawalec; Spencer B Gibson; Richard Keijzer; Ayesha Saleem; Grant M Hatch; Christine A Doucette; Jason M Karch; Vernon W Dolinsky; Ian M Dixon; Adrian R West; Christof Rampitsch; Joseph W Gordon Journal: Cell Death Dis Date: 2021-11-26 Impact factor: 8.469
Authors: Gustavo Jose Justo da Silva; Raffaele Altara; George W Booz; Alessandro Cataliotti Journal: Front Physiol Date: 2021-07-08 Impact factor: 4.566